Login Register Cart 0
Generic placeholder image

Current Women`s Health Reviews

Editor-in-Chief

ISSN (Print): 1573-4048
ISSN (Online): 1875-6581

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Advanced Ovarian Cancer: A 2-year Survival Analysis Study

Author(s): Farah Farzaneh, Azadeh Jafari Ashtiani*, Mehrdad Bohlooli and Maryam Sadat Hosseini

Volume 20, Issue 4, 2024

Published on: 11 September, 2023

Article ID: e220823220203 Pages: 10

DOI: 10.2174/1573404820666230822145758

Price: $65

conference banner
Abstract

Background: During the last few years, Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has entered the national comprehensive cancer network guidelines as a new protocol for improving patients’ outcomes. However, there is no consensus on its long-term efficiency, and it still is under debate.

Objectives: This study aims to evaluate the effectiveness of Cytoreductive Surgery Plus hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer in Iran.

Method: Thirty patients with Stage IIIc and IV advanced ovarian cancer underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at Jam Hospital with a fixed surgical team in Tehran, Iran, from 2019 to 2021. Fourteen patients were new cases, and sixteen of them were recurrent cases. At the end of cytoreductive surgery, by using a hyperthermic intraperitoneal chemotherapy device, Cisplatin was circulated in the peritoneal cavity for 90 minutes at a dose of 80-100 mg/ m2 at 43°C.

Results: Among 30 patients with 54.97±10.74 years of mean age, the mean overall survival was 564.967 days, and 2-year survival rates were 66.7%. According to Fisher's exact test, there was a statistically significant relationship between disease-free after surgery and mortality rate (p=0.00). However, there was no statistically significant relationship between recurrence after surgery and mortality rate (p=0.093).

Conclusion: Based on these findings, cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy had a survival rate of 66.7% within two years in advanced ovarian cancer patients. However, to achieve better results, careful selection of patients and complete cytoreductive surgery should be performed.

Keywords: Cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, advanced ovarian cancer, peritoneal cavity, adjuvant chemotherapy, cellular proteins.

Graphical Abstract

[1]
Lheureux, S.; Gourley, C.; Vergote, I.; Oza, A.M. Epithelial ovarian cancer. Lancet, 2019, 393(10177), 1240-1253.
[http://dx.doi.org/10.1016/S0140-6736(18)32552-2] [PMID: 30910306]
[2]
Obermair, A.; Beale, P.; Scott, C.L.; Beshay, V.; Kichenadasse, G.; Simcock, B.; Nicklin, J.; Lee, Y.C.; Cohen, P.; Meniawy, T. Insights into ovarian cancer care: Report from the ANZGOG Ovarian Cancer Webinar Series 2020. J. Gynecol. Oncol., 2021, 32(6), e95.
[http://dx.doi.org/10.3802/jgo.2021.32.e95] [PMID: 34708597]
[3]
Pecorelli, S.; Favalli, G.; Gadducci, A.; Katsaros, D.; Panici, P.B.; Carpi, A.; Scambia, G.; Ballardini, M.; Nanni, O.; Conte, P. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: Final results of the After-6 protocol 1. J. Clin. Oncol., 2009, 27(28), 4642-4648.
[http://dx.doi.org/10.1200/JCO.2009.21.9691] [PMID: 19704064]
[4]
Malik, I.A. A prospective study of clinico-pathological features of epithelial ovarian cancer in Pakistan. J. Pak. Med. Assoc., 2002, 52(4), 155-158.
[PMID: 12174480]
[5]
Vergote, I.; Coens, C.; Nankivell, M.; Kristensen, G.B.; Parmar, M.K.B.; Ehlen, T.; Jayson, G.C.; Johnson, N.; Swart, A.M.; Verheijen, R.; McCluggage, W.G.; Perren, T.; Panici, P.B.; Kenter, G.; Casado, A.; Mendiola, C.; Stuart, G.; Reed, N.S.; Kehoe, S.; Tropé, G. C.; Dobbs, S.; Essapen, S.; Hoskins, P.; Green, J.; Gilby, E.; Van Baal, M.; Twigg, J.; Van Der Burg, M.E.L.; Godfrey, K.; Lacave, A.J.; Angioli, R.; Nath, R.; Chin, K.; Redman, C.; Lotocki, R.; Olaitan, A.; Mosgaard, B.; Rustin, G.; Ind, T.; Persic, M.; Hogg, M.; Van Der Velden, J.; Ledermann, J.; Peter Sykes, P.S.; Madhavan, K.; Kannisto, P.; Hird, V.; Evans, A.; Sandvei R, R.; Gauthier, P.; Cruickshank, D.J.; Ottevanger, P.B.; Pearson, S.; Kitchener, H.; Hall, M.; Bessette, P.; Pecorelli, S.; Gerdin, E.; Lopes, T.; Fish, A.; Barlow, C.; Van Eygen, K.; Floquet, A.; Tholander, B.; Gul, N.; Gornall, R.; Luesley, D.; Kirwan, P.; Symonds, P.; Henry, R.; Poole, D.; McNeish, I.; Hocking, M.; Sammaraie, A.; Speiser, P.; Leblanc, E.; Green, J.A.; De Oliveira, C.F.; Grimshaw, R.; Zola, P.; Parkin, D.; Luesley, D.; Lamb, M.; Hong, A.; Gillespie, A.; Hamid, A.; Ahmed, A.; Plante, M.; De Valk, B.; Nordin, A.; Clamp, A.; Perez, D.; Graham Dark, G.D.; Ferguson, M.; MacGregor, C.; Skailes, G.; Jones, R.; Gillespie, A.; Cawdell, G.; Leeson, S.; Elit, L.; Dittrich, C.; Gotlieb, W.; Poole, D.; Cullimore, J.; Crosse, B.; Ridley, P.; Head, A.; Nieto, J.; Awwad, S.; Brinkmann, D.; Eustace, D.; Hindley, A.; Katsaros, D.; Popadiuk, C.; Kristeller, T.; Redman, C.; Chan, S.; Marth, C.; Yiannakis, D.; Lankaster, K.; Beynon, G.; Suhail, A.; Indrajit, F.; Hong, A.; Quigley, M.; Adeyemi, O.; Persic, M.; Lofts, F.; McNally, O.; Tristam, A.; Lee, M.; Counsell, R.; Gleeson, N.; Papadopoulos, A.; Maggino, T.; Honkoop, A.; Ghatage, P.; Vermorken, J.B.; De Greve, J.; Boman, K.; Petru, E.; Amant, F. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol., 2018, 19(12), 1680-1687.
[http://dx.doi.org/10.1016/S1470-2045(18)30566-7] [PMID: 30413383]
[6]
Lheureux, S.; Braunstein, M.; Oza, A.M. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J. Clin., 2019, 69(4), caac.21559.
[http://dx.doi.org/10.3322/caac.21559] [PMID: 31099893]
[7]
Sureka, B.; Meena, V.; Garg, P.; Yadav, T.; Khera, P.S. Computed tomography imaging of ovarian peritoneal carcinomatosis: a pictorial review. Pol. J. Radiol., 2018, 83, 500-509.
[http://dx.doi.org/10.5114/pjr.2018.80247] [PMID: 30655930]
[8]
Ray, M. Palliative Care of Patients with Ovarian Cancer. In: Multidisciplinary Approach to Surgical Oncology Patients; Springer, 2021; pp. 243-249.
[9]
van Baal, J.O.A.M.; van Noorden, C.J.F.; Nieuwland, R.; Van de Vijver, K.K.; Sturk, A.; van Driel, W.J.; Kenter, G.G.; Lok, C.A.R. Development of peritoneal carcinomatosis in epithelial ovarian cancer: a review. J. Histochem. Cytochem., 2018, 66(2), 67-83.
[http://dx.doi.org/10.1369/0022155417742897] [PMID: 29164988]
[10]
Palaia, I.; Tomao, F.; Sassu, C.M.; Musacchio, L.; Benedetti Panici, P. Immunotherapy for ovarian cancer: Recent advances and combination therapeutic approaches. OncoTargets Ther., 2020, 13, 6109-6129.
[http://dx.doi.org/10.2147/OTT.S205950] [PMID: 32617007]
[11]
Najafi, N.; Gharib, M.; Nematollahi, N.; Mehravar, F. Preoperative evaluation of pelvic MRI findings in patients with rectosigmoid cancer in golestan province, North of Iran. Novelty in Clinical Medicine, 2022, 1(3), 127-134.
[12]
Chan, J.K.; Cheung, M.K.; Husain, A.; Teng, N.N.; West, D.; Whittemore, A.S.; Berek, J.S.; Osann, K. Patterns and progress in ovarian cancer over 14 years. Obstet. Gynecol., 2006, 108(3, Part 1), 521-528.
[http://dx.doi.org/10.1097/01.AOG.0000231680.58221.a7] [PMID: 16946210]
[13]
Ovarian cancer: An integrated review. In: Stewart, C.; Ralyea, C.; Lockwood, S., Eds.; Seminars in oncology nursing; Elsevier, 2019.
[14]
Friedlander, M.; Matulonis, U.; Gourley, C.; du Bois, A.; Vergote, I.; Rustin, G.; Scott, C.; Meier, W.; Shapira-Frommer, R.; Safra, T.; Matei, D.; Shirinkin, V.; Selle, F.; Fielding, A.; Lowe, E.S.; McMurtry, E.L.; Spencer, S.; Rowe, P.; Mann, H.; Parry, D.; Ledermann, J. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br. J. Cancer, 2018, 119(9), 1075-1085.
[http://dx.doi.org/10.1038/s41416-018-0271-y] [PMID: 30353045]
[15]
Pignata, S; Cecere, S; Du Bois, A; Harter, P; Heitz, F Treatment of recurrent ovarian cancer. Ann Oncol., 2017, 28(S8), viii51-viii56.
[http://dx.doi.org/10.1093/annonc/mdx441]
[16]
Burges, A.; Schmalfeldt, B. Ovarian cancer: Diagnosis and treatment. Dtsch. Arztebl. Int., 2011, 108(38), 635-641.
[PMID: 22025930]
[17]
Kuroki, L.; Guntupalli, S.R. Treatment of epithelial ovarian cancer. BMJ, 2020, 371, m3773.
[http://dx.doi.org/10.1136/bmj.m3773] [PMID: 33168565]
[18]
Tian, H.; Yan, L.; Xiao-fei, L.; Hai-yan, S.; Juan, C.; Shan, K. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer. Clin. Epigenetics, 2019, 11(1), 153.
[http://dx.doi.org/10.1186/s13148-019-0748-4] [PMID: 31666131]
[19]
Cianci, S.; Riemma, G.; Ronsini, C.; De Franciscis, P.; Torella, M.; Schiattarella, A.; La Verde, M.; Colacurci, N. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer recurrence: Systematic review and meta-analysis. Gland Surg., 2020, 9(4), 1140-1148.
[http://dx.doi.org/10.21037/gs-20-335] [PMID: 32953629]
[20]
Bakrin, N.; Tempfer, C.; Scambia, G.; De Simone, M.; Gabriel, B.; Grischke, E.M.; Rau, B. PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Pleura Peritoneum, 2018, 3(3), 20180114.
[http://dx.doi.org/10.1515/pp-2018-0114] [PMID: 30911662]
[21]
Alter, R; Turaga, K; Lengyel, E Are we ready for hyperthermic intraperitoneal chemotherapy in the upfront treatment of ovarian cancer? JAMA Netw. Open, 2020, 3(8), e2014184.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.14184]
[22]
Rihuete Caro, C.; Manzanedo, I.; Pereira, F.; Carrion-Alvarez, L.; Serrano, Á.; Pérez-Viejo, E. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. Eur. J. Surg. Oncol., 2018, 44(11), 1805-1810.
[http://dx.doi.org/10.1016/j.ejso.2018.06.036] [PMID: 30087071]
[23]
Charo, L.M.; Jou, J.; Binder, P.; Hohmann, S.F.; Saenz, C.; McHale, M.; Eskander, R.N.; Plaxe, S. Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States. Gynecol. Oncol., 2020, 159(3), 681-686.
[http://dx.doi.org/10.1016/j.ygyno.2020.09.022] [PMID: 32977989]
[24]
Riggs, M.J.; Pandalai, P.K.; Kim, J.; Dietrich, C.S. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. Diagnostics, 2020, 10(1), 43.
[http://dx.doi.org/10.3390/diagnostics10010043] [PMID: 31947647]
[25]
Regimbeau, M.; Abrey, J.; Vautrot, V.; Causse, S.; Gobbo, J.; Garrido, C. Heat shock proteins and exosomes in cancer theranostics. In: Seminars in Cancer Biology; Elsevier, 2021.
[26]
Fader, A.N.; Rose, P.G. Role of surgery in ovarian carcinoma. J. Clin. Oncol., 2007, 25(20), 2873-2883.
[http://dx.doi.org/10.1200/JCO.2007.11.0932] [PMID: 17617518]
[27]
Gill, R.S.; Al-Adra, D.P.; Nagendran, J.; Campbell, S.; Shi, X.; Haase, E.; Schiller, D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A systematic review of survival, mortality, and morbidity. J. Surg. Oncol., 2011, 104(6), 692-698.
[http://dx.doi.org/10.1002/jso.22017] [PMID: 21713780]
[28]
Yang, L.; Zhang, B.; Xing, G.; Du, J.; Yang, B.; Yuan, Q.; Yang, Y. Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome. PLoS One, 2017, 12(10), e0186725.
[http://dx.doi.org/10.1371/journal.pone.0186725] [PMID: 29059209]
[29]
van Driel, W.J.; Koole, S.N.; Sikorska, K.; van Leeuwen, S.J.H.; Schreuder, H.W.R.; Hermans, R.H.M.; de Hingh, I.H.J.T.; van der Velden, J.; Arts, H.J.; Massuger, L.F.A.G.; Aalbers, A.G.J.; Verwaal, V.J.; Kieffer, J.M.; Van de Vijver, K.K.; van Tinteren, H.; Aaronson, N.K.; Sonke, G.S. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl. J. Med., 2018, 378(3), 230-240.
[http://dx.doi.org/10.1056/NEJMoa1708618] [PMID: 29342393]
[30]
Mercier, F.; Bakrin, N.; Bartlett, D.L.; Goere, D.; Quenet, F.; Dumont, F.; Heyd, B.; Abboud, K.; Marolho, C.; Villeneuve, L.; Glehen, O. Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multi-institutional cohort from PSOGI and BIG-RENAPE. Ann. Surg. Oncol., 2018, 25(6), 1668-1675.
[http://dx.doi.org/10.1245/s10434-018-6464-z] [PMID: 29637438]
[31]
Malgras, B.; Gayat, E.; Aoun, O.; Lo Dico, R.; Eveno, C.; Pautrat, K.; Delhorme, J.B.; Passot, G.; Marchal, F.; Sgarbura, O.; Ferron, G.; Goéré, D.; Andre, T.; Pocard, M. Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): The RENAPE study. Ann. Surg. Oncol., 2018, 25(11), 3271-3279.
[http://dx.doi.org/10.1245/s10434-018-6631-2] [PMID: 29978366]
[32]
Wang, Y.; Ren, F.; Chen, P.; Liu, S.; Song, Z.; Ma, X. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis. Eur. J. Surg. Oncol., 2019, 45(3), 301-309.
[http://dx.doi.org/10.1016/j.ejso.2018.10.528] [PMID: 30786961]
[33]
Deraco, M.; Sinukumar, S.; Salcedo-Hernández, R.A.; Rajendra, V.J.; Baratti, D.; Guaglio, M.; Nizri, E.; Kusamura, S. Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experience. Eur. J. Surg. Oncol., 2019, 45(11), 2103-2108.
[http://dx.doi.org/10.1016/j.ejso.2019.06.021] [PMID: 31230982]
[34]
Petrillo, M.; Anchora, L.P.; Scambia, G.; Fagotti, A. Cytoreductive surgery plus platinum-based hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: A promising integrated approach to improve locoregional control. Oncologist, 2016, 21(5), 532-534.
[http://dx.doi.org/10.1634/theoncologist.2015-0500] [PMID: 27009941]
[35]
Helm, C.W. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist, 2009, 14(7), 683-694.
[http://dx.doi.org/10.1634/theoncologist.2008-0275] [PMID: 19608639]
[36]
Shi, T.; Jiang, R.; Pu, H.; Yang, H.; Tu, D.; Dai, Z.; Cai, Y.; Zhang, Y.; Cheng, X.; Jia, H.; Tu, R.; Wang, H.; Tang, J.; Luan, Y.; Cai, S.; Zang, R. Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: A randomised controlled study. Br. J. Cancer, 2019, 121(5), 425-428.
[http://dx.doi.org/10.1038/s41416-019-0543-1] [PMID: 31383985]
[37]
Di Giorgio, A.; De Iaco, P.; De Simone, M.; Garofalo, A.; Scambia, G.; Pinna, A.D.; Verdecchia, G.M.; Ansaloni, L.; Macrì, A.; Cappellini, P.; Ceriani, V.; Giorda, G.; Biacchi, D.; Vaira, M.; Valle, M.; Sammartino, P. Cytoreduction (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: Retrospective Italian multicenter observational study of 511 cases. Ann. Surg. Oncol., 2017, 24(4), 914-922.
[http://dx.doi.org/10.1245/s10434-016-5686-1] [PMID: 27896512]
[38]
Rettenmaier, M.A.; Micha, J.P.; Bohart, R.; Goldstein, B.H. A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol., 2020, 244, 101-105.
[http://dx.doi.org/10.1016/j.ejogrb.2019.10.047] [PMID: 31778904]
[39]
Zhang, J.; Li, X-b.; Ji, Z-h.; Ma, R.; Bai, W-p.; Li, Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival with acceptable safety for advanced ovarian cancer: A clinical study of 100 patients. BioMed Res. Int., 2021, 2021, 5533134.
[40]
Biacchi, D.; Accarpio, F.; Ansaloni, L.; Macrì, A.; Ciardi, A.; Federici, O.; Spagnoli, A.; Cavaliere, D.; Vaira, M.; Sapienza, P.; Sammartino, P. Upfront debulking surgery versus interval debulking surgery for advanced tubo‐ovarian high‐grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC. J. Surg. Oncol., 2019, 120(7), 1208-1219.
[http://dx.doi.org/10.1002/jso.25703] [PMID: 31531879]
[41]
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0; U.S. Department Of Health And Human Services, 2020.
[42]
Manzanedo, I.; Pereira, F.; Pérez-Viejo, E.; Serrano, Á.; Hernández-García, M.; Martínez-Torres, B.; Rihuete-Caro, C.; Calzas, J.; Cueto, M. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer. Minerva Ginecol., 2017, 69(2), 119-127.
[PMID: 27415829]

Rights & Permissions Print Cite
Article Metrics
8
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy